1/ Early commercialisation is not bad. It expands our surface area for upside optionality. Exposure to the market opens doors to unexpected opportunities and serendipity. Embrace randomness as a source of innovation. 2/ The superfluous often seems unnecessary, but it’s this excess that serves as combinatorial fodder for future breakthroughs. Don’t dismiss what seems extraneous; it might spark the next big idea. 3/ Impostor syndrome is a common experience. Acknowledge it, but balance it with truth and specificity. This balance ensures we deliver on our promises and set the right expectations. 4/ Early market exposure teaches us what works and what doesn’t in real-world scenarios. It’s a valuable learning experience that can refine our approach and drive success. 5/ By embracing early commercialisation, we increase our chances of discovering new pathways and solutions that might not be evident in a controlled environment. Innovation thrives in the wild. 6/ In summary: Early commercialisation = increased upside potential, learning through exposure, leveraging randomness for innovation, and balancing confidence with realistic expectations. [[Focus and No Change]] | [[Order for Chaos]] | [[Here to Stay]]